A Phase <scp>II</scp> Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis

Fleischmann, Roy; Bliddal, Henning; J. Blanco, Francisco; J. Schnitzer, Thomas; G. Peterfy, Charles; Chen, Su; Wang, Li; Feng, Sheng; G. Conaghan, Philip; Berenbaum, Françis; Pelletier, Jean‐Pierre; Martel‐Pelletier, Johanne; Vaeterlein, Ole; S. Kaeley, Gurjit; Liu, Wei; P. Kosloski, Matthew; Levy, G; Zhang, Lanju; K. Medema, Jeroen; C. Levesque, Marc

doi:10.1002/art.40840

Public

A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis

Published in Arthritis & Rheumatology • Jan 17, 2019

Authors:

Roy Fleischmann

Henning Bliddal

Francisco J. Blanco

Abstract

OBJECTIVE: To assess the efficacy and safety of the anti-interleukin-1α/β (anti-IL-1α/β) dual variable domain immunoglobulin lutikizumab (ABT-981) in patients with knee osteoarthritis (OA) and evidence of synovitis. METHODS: Patients (n = 350; 347 analyzed) with Kellgren/Lawrence grade 2-3 knee OA a...

Subject

Synovitis

Osteoarthritis

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!